Merck & Co. Inc. ( MRK ) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve).

• MRK shares are experiencing downward pressure. Check out the latest moves here.

The success criterion for the primary efficacy hypothesis, as measured by the percentage of participants with HIV-1 RNA levels